Why Modern Enterprises Choose Drupal
More Than a CMS. A Composable Digital Experience Platform.
When your digital needs outgrow basic templates and rigid systems, you need a platform engineered for flexibility, scalability, and integration. Drupal is the open-source powerhouse chosen by global enterprises to build digital experiences that are secure, adaptable, and built to last.
Recent releases
|
AI and Digital Transformation in 2026
Your organization has invested in AI tools. Reports promised transformation. Yet many initiatives still deliver fragmented results. You see the potential. You also see the stalls.AI and digital…
AI Integration in Insurance: What Works in 2026
Claims backlogs grow. Underwriting decisions take weeks. Fraud slips through cracks.This is the daily pressure AI integration in insurance was built to solve. It embeds agentic AI, generative models…
|
AI Automation 2026: Closing the Maturity Divide
The Fundamentals of AI AutomationLeading sources define AI automation as the integration of machine learning and natural language processing with robotic process automation. It moves beyond rigid…
AI Integration in Finance: What Works in 2026
Finance teams already drown in data. Yet decisions still take days. Fraud slips through. Compliance audits drag on.This is the exact pain AI integration in finance was designed to solve. It connects…
CASE STUDY
See all our work
How a Top Indian Pharma Brand Boosted HCP Engagement Using Tech-Led Omnichannel Marketing
India’s renowned pharmaceutical company, known for its strong presence in chronic therapy areas, was facing a growing disconnect with its most important audience: healthcare professionals.
How a Leading Indian Pharma Brand Expanded Reach Across Semi-Urban & Rural Regions
A leading pharmaceutical company in India, well known for its OTC presence and deep connection with mass-market audiences, was preparing to launch a public awareness campaign focused on maternal he
Driving Digital Engagement for a Chronic Care Program with Tech-Led Pharma Marketing
A leading pharmaceutical company in India, known for its chronic care drug portfolio, was preparing to launch a support program aimed at patients diagnosed with congestive heart failure (CHF).
